Industry leaders like to use phrases such as "going forward" and "as the company evolves," even though a troubling number of firms in biotechnology (and other industries) tend instead to stall, slide or die.
Amgen Inc. launched a $100 million venture capital fund for start-up biotechnology firms that will let the West Coast giant get a piece of the early stage action as far away as Boston. (BioWorld Today)
RSS